Health Care
Authors
Beth Duff-Brown
News Type
News
Date
Paragraphs

Herman Shaw was a 30-year-old cotton farmer in Tuskegee, Alabama, when he saw a flyer offering free medical care by the U.S. government.

This was back in 1932 and the Great Depression was bearing down hard on the already poor black farmers in the Deep South. Shaw jumped at what he said seemed like a godsend at the time.

“Every year they would give us a full examination and a free meal,” Shaw told The Baltimore Sun for a story in 1997. The men were also offered free burial insurance.

What Shaw would learn 40 years later was the U.S. Public Health Service was unwittingly testing him for syphilis, a little-understood sexually transmitted disease that was devastating black communities in rural Alabama.

What’s worse, even after Shaw tested positive for the disease — which can cause blindness, paralysis, heart failure, bone deformities and even death if left unchecked — he was never told, nor treated.

“The thing that disturbs me now is that they found a cure,” Shaw told the Baltimore Sun. “They found penicillin. And they never gave it to us. It vexed me awfully sadly.”

Shaw was one of the 600 African-American men chosen for the “Tuskegee Study of Untreated Syphilis in the Negro Male.” They were told they had “bad blood” and many underwent painful spinal taps. Of those 600 men, 399 had syphilis.

Even after the Centers for Disease Control in 1945 approved penicillin to treat the disease, the study that began in 1932 would continue until 1972 without the men being treated — all in the name of medical research.

barber best2 Stanford sophomore Javarcia Ivory (right) talks to a patron of the Station 33 Barber Shop in downtown Oakland for the Oakland Health Disparities Pilot Project. Photo by Nicole Feldman

Stanford sophomore Javarcia Ivory (biology, ’19), remembers hearing this medical horror story growing up in neighboring Mississippi. He vowed to become a doctor and help revive the lost trust in public health in the Deep South.

When Ivory learned about a Stanford-led research project in Oakland, one that would dig deeper into this legacy of mistrust stemming from Tuskegee, he jumped.

“As an African-American and someone who aspires to one day become a doctor, I just knew I had to get involved,” he said.

Researchers connect Tuskegee trials to lower life expectancy

“The (Tuskegee) study’s methods have become synonymous with exploitation and mistreatment by the medical community,” write Stanford Health Policy’s Marcella Alsan and her colleague Marianne Wanamaker at the University of Tennessee.

The two have found that the disclosure of the study in 1972 is correlated with increases in medical mistrust and mortality among African-American men. They published their findings in a working paper for the National Bureau of Economic Research last year.

Using publicly accessible data, the researchers estimated life expectancy at age 45 for black men fell by up to 1.4 years in response to the disclosure, accounting for about 35 percent of the 1980 life-expectancy gap between black and white men.

Alsan and Wanamaker used data on medical trust, migration and health utilization from the General Social Survey and the National Health Interview Survey, as well as morbidity and mortality data from the Centers for Disease Control and Prevention.

Their paper touched a nerve among some prominent African-Americans, some of whom praised the work as a model for understanding medical mistrust today.

“The story that Alsan and Wanamaker uncovered is even deeper than the direct effects of the Tuskegee Study,” wrote Vann R. Newkirk II in the Atlantic.

“Their research helps validate the anecdotal experiences of physicians, historians, and public health workers in black communities and gives new power to them,” Newkirk wrote. “These findings are also useful in framing health-care debates and discussions of health disparities today.”

Health disparities run deep

African-American men today have the worst health outcomes of all major ethnic, racial and demographic groups in the United States. Life expectancy for black men at age 45 is three years less than their white male peers, and five years less than for black women.

In the years following the disclosure of the Tuskegee trials, medical researchers have repeatedly pointed to the U.S. Public Health Service experiment as one reason African-Americans remain wary of mainstream medicine and health-care providers.

Image

“Mistrust may function as a tax on the price you pay to see a doctor,” said Alsan.

To further test this hypothesis beyond their data research, Alsan launched a pilot project in Oakland this past summer to evaluate the willingness of black men to seek preventative medical screenings.

The Oakland Health Disparities Pilot Project partnered with Dr. Owen Garrick, president and COO of Bridge Clinical Research, an organization based in Oakland that helps clinical researchers find patients from targeted ethnic groups.

Alsan and Garrick worked alongside Stanford and UC Berkeley students, as well as recent EMT students from the Oakland community to help run the project.

“We believe that even if you remove all the obstacles: transportation, access to health care and insurance — if you don’t trust the provider, you won’t follow their advice,” said Garrick, a physician whose mission is to get more people of color involved in clinical trials.

“But if you can push through this issue of mistrust, then you really begin to reap the benefits of the wealth of our health-care system, and then take advantage of the things that we as Americans have been afforded,” he said.

Oakland barbers partnered with the researchers and the barbershops served as recruitment sites. Uber also donated rides to the clinic for screening services.

Some 200 men filled out a medical survey; of those, 60 then agreed to clinical care.

Chris Colter, a master barber and manager for Station 33 Barber Shop in downtown Oakland, was pleased to participate in the pilot.

“It feels good that we’re helping out the community and that we’re instrumental in helping black men with health issues,” said Colter.

The pilot results are encouraging, Alsan said, given the high number of those who took up the offer for medical screenings. The team is hoping to scale up the research if they secure additional funding.

Ivory spent his summer in the Oakland barbershops, urging patrons to fill out the surveys and get the free checkup.

“I was really surprised at how easily they opened up with me and how interested they were that I went to Stanford,” said Ivory, who intends to go to medical school and return to rural Mississippi to practice medicine.

African-American men have a 70 percent higher risk of developing heart failure than white men, prompting Ivory’s desire to become a cardiologist.

“Working in the barbershops really gave me an in-depth understanding of how important diversity and inclusion in medicine are for some American populations,” said Ivory. “Medical mistrust does not have to dissuade black men from seeking health care in contemporary America — but it does. And this has galvanized my passion for wanting to become a doctor.”

Image
javarcia owen

Berkeley graduate student Grant Graziani, three years into a PhD in economics with a focus on health policy, helped design and implement the Oakland study.

“One area that I think has gotten too little study is how race affects health outcomes,” said Graziani. “I think really zooming in on race and studying a diverse population pool is going to open up a new area of research with a lot of interesting policy implications. Ultimately we just want to help people have healthier lives.”

A Presidential Apology

Shaw was one of eight Tuskegee survivors invited to a White House ceremony in 1997, to meet President Bill Clinton, who formally apologized for one of the most macabre clinical trials in American history.

The last of the Tuskegee survivors, Ernest Hendon, died in 2004 at the age of 96.

Ninety-four-year-old Herman Shaw (R) embraces President Bill Clinton after receiving a public apology for being victimized in the Tuskegee Syphilis Study in ceremonies at the White House in Washington, D.C. on May 16, 1997. For almost 40 years, Shaw and 600 other black men were part of a government study following the progression of syphilis, who were told they were being treated, but were not. Photo: Stephen Jaffe/AFP/Getty Images

“The wounds that were inflicted upon us cannot be undone,” Shaw said at the White House ceremony, after being helped to the podium by Clinton. “I’m saddened today to think of those who did not survive and whose families will forever live with the knowledge that their death and suffering was preventable.”

The valedictorian of his 1922 high school class had wanted to go to college to study engineering, but his father insisted he stay back to run the family farm. He died in 1999 at the age of 97.

Two years earlier, at the White House ceremony, Shaw still found it in his heart to say it was never too late to “restore faith and trust.”

“In order for America to reach its full potential, “Shaw said, “we must truly be one America — black, red, white together — trusting each other, caring for each other, and never allowing the kind of tragedy which has happened to us in the Tuskegee study to ever happen again."

Hero Image
barbershop best
Chris Colter (right), a master barber and manager at the Station 33 Barber Shop in downtown Oakland with a customer. He helped the researchers recruit African-American men for the Oakland Health Disparities Pilot Project.
Nicole Feldman
All News button
1
Paragraphs

Importance:

Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care.

Objective:

To examine the association of outcomes and medical expenditures with a bundled-payment pay-for-performance program for breast cancer in Taiwan compared with a fee-for-service (FFS) program.

Design, Setting, and Participants:

Data were obtained from the Taiwan Cancer Database, National Health Insurance Claims Data, the National Death Registry, and the bundled-payment enrollment file. Women with newly diagnosed breast cancer and a documented first cancer treatment from January 1, 2004, to December 31, 2008, were selected from the Taiwan Cancer Database and followed up for 5 years, with the last follow-up data available on December 31, 2013. Patients in the bundled-payment program were matched at a ratio of 1:3 with control individuals in an FFS program using a propensity score method. The final sample of 17 940 patients included 4485 (25%) in the bundled-payment group and 13 455 (75%) in the FFS group.

Main Outcomes and Measures:

Rates of adherence to quality indicators, survival rates, and medical payments (excluding bonuses paid in the bundled-payment group). The Kaplan-Meier method was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox proportional hazards regression model was used to examine the effect of the bundled-payment program on overall and event-free survival. Sensitivity analysis for bonus payments in the bundled-payment group was also performed.

Results:

The study population included 17 940 women (mean [SD] age, 52.2 [10.3] years). In the bundled-payment group, 1473 of 4215 patients (34.9%) with applicable quality indicators had full (100%) adherence to quality indicators compared with 3438 of 12 506 patients (27.5%) with applicable quality indicators in the FFS group (P < .001). The 5-year event-free survival rates for patients with stages 0 to III breast cancer were 84.48% for the bundled-payment group and 80.88% for the FFS group (P < .01). Although the 5-year medical payments of the bundled-payment group remained stable, the cumulative medical payments for the FFS group steadily increased from $16 000 to $19 230 and exceeded pay-for-performance bundled payments starting in 2008.

Conclusions and Relevance:

In Taiwan, compared with the regular FFS program, bundled payment may lead to better adherence to quality indicators, better outcomes, and more effective cost-control over time.

 

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Journal of the American Medical Association (JAMA) Oncology
Authors
C. Jason Wang
Paragraphs

Background

Prior studies have reported that more than 20% of implantable cardioverter-defibrillator (ICD) implantations in the United States do not adhere to trial-based criteria.

Objective

We sought to investigate the patient characteristics associated with not meeting the inclusion criteria of the clinical trials that have demonstrated the efficacy of primary prevention ICDs.

Methods

Using data from the National Cardiovascular Data Registry’s ICD Registry, we identified patients who received ICDs for primary prevention from January 2006 to December 2008. We determined whether patients met the inclusion criteria of at least 1 of the 4 ICD primary prevention trials: Multicenter Automatic Defibrillator Implantation Trial (MADIT), MADIT-II, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), and the Multicenter Unsustained Tachycardia Trial (MUSTT).

Results

Among 150,264 patients, 86% met criteria for an ICD implantation based on trial data. The proportion of patients who did not meet trial-based criteria increased as age decreased. In multivariate analysis, the significant predictors for not meeting trial criteria included prior cardiac transplantation (odds ratio [OR] 2.1), pediatric electrophysiology operator (OR 2.0), and high-grade atrioventricular conduction disease (OR 1.4).

Conclusion

Among National Cardiovascular Data Registry registrants receiving first-time ICDs for primary prevention, the majority met trial-based criteria. Multivariate analyses suggested that many patients who did not meet the trial-based criteria may have had clinical circumstances that warranted ICD implantation. These findings caution against the use of trial-based indications to determine site quality metrics that could penalize sites that care for younger patients. The planned incorporation of appropriate use criteria into the ICD registry may better characterize patient- and site-level quality and performance.

 

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Heart Rhythm
Authors
Paul A. Heidenreich
Mary K. Goldstein
Mintu Turakhia
Paragraphs

Objectives: Unwarranted geographic variation in spending has received intense scrutiny in the United States. However, few studies have compared variation in spending and surgical outcomes between the United States healthcare system and those of other nations. In this study, we compare the geographic variation in postsurgical outcomes and cost between the United States and Japan.

Study Design: This retrospective cohort study uses Medicare Part A data from the United States (2010-2011) and similar inpatient data from Japan (2012). Patients 65 years or older undergoing 1 of 5 surgeries (coronary artery bypass graft, abdominal aortic aneurysm repair, colectomy, pancreatectomy, or gastrectomy) were selected in the United States and Japan.

Methods: Reliability- and case-mix–adjusted coefficient of variation (COV) values were calculated using hierarchical modeling and empirical Bayes techniques for the following 5 outcomes: postoperative mortality, the development of a complication, death after complication (failure to rescue), length of stay, and the cost of the hospitalization. Sensitivity analyses were also performed by calculating patient demographic-and case-mix–adjusted COV values for each outcome using weighted age- and sex-standardized values.

Results: The variability of the postsurgical outcomes was uniformly lower in the United States compared with Japan. Cost variation was consistently higher in the United States for all surgeries.

Conclusions: Although the US healthcare system may be more inefficient regarding costs, the presence of higher geographic variation in postoperative care in Japan, relative to the United States, suggests that the observed geographic variation in the United States—both for health expenditures and outcomes—is not a unique manifestation of its structural shortcomings.

- See more at: http://www.ajmc.com/journals/issue/2016/2016-vol22-n9/geographic-variat…

Objectives: Unwarranted geographic variation in spending has received intense scrutiny in the United States. However, few studies have compared variation in spending and surgical outcomes between the United States healthcare system and those of other nations. In this study, we compare the geographic variation in postsurgical outcomes and cost between the United States and Japan.

Study Design: This retrospective cohort study uses Medicare Part A data from the United States (2010-2011) and similar inpatient data from Japan (2012). Patients 65 years or older undergoing 1 of 5 surgeries (coronary artery bypass graft, abdominal aortic aneurysm repair, colectomy, pancreatectomy, or gastrectomy) were selected in the United States and Japan.

Methods: Reliability- and case-mix–adjusted coefficient of variation (COV) values were calculated using hierarchical modeling and empirical Bayes techniques for the following 5 outcomes: postoperative mortality, the development of a complication, death after complication (failure to rescue), length of stay, and the cost of the hospitalization. Sensitivity analyses were also performed by calculating patient demographic-and case-mix–adjusted COV values for each outcome using weighted age- and sex-standardized values.

Results: The variability of the postsurgical outcomes was uniformly lower in the United States compared with Japan. Cost variation was consistently higher in the United States for all surgeries.

Conclusions: Although the US healthcare system may be more inefficient regarding costs, the presence of higher geographic variation in postoperative care in Japan, relative to the United States, suggests that the observed geographic variation in the United States—both for health expenditures and outcomes—is not a unique manifestation of its structural shortcomings.

- See more at: http://www.ajmc.com/journals/issue/2016/2016-vol22-n9/geographic-variat…

Objectives: Unwarranted geographic variation in spending has received intense scrutiny in the United States. However, few studies have compared variation in spending and surgical outcomes between the United States healthcare system and those of other nations. In this study, we compare the geographic variation in postsurgical outcomes and cost between the United States and Japan.

Study Design: This retrospective cohort study uses Medicare Part A data from the United States (2010-2011) and similar inpatient data from Japan (2012). Patients 65 years or older undergoing 1 of 5 surgeries (coronary artery bypass graft, abdominal aortic aneurysm repair, colectomy, pancreatectomy, or gastrectomy) were selected in the United States and Japan.

Methods: Reliability- and case-mix–adjusted coefficient of variation (COV) values were calculated using hierarchical modeling and empirical Bayes techniques for the following 5 outcomes: postoperative mortality, the development of a complication, death after complication (failure to rescue), length of stay, and the cost of the hospitalization. Sensitivity analyses were also performed by calculating patient demographic-and case-mix–adjusted COV values for each outcome using weighted age- and sex-standardized values.

Results: The variability of the postsurgical outcomes was uniformly lower in the United States compared with Japan. Cost variation was consistently higher in the United States for all surgeries.

Conclusions: Although the US healthcare system may be more inefficient regarding costs, the presence of higher geographic variation in postoperative care in Japan, relative to the United States, suggests that the observed geographic variation in the United States—both for health expenditures and outcomes—is not a unique manifestation of its structural shortcomings.

- See more at: http://www.ajmc.com/journals/issue/2016/2016-vol22-n9/geographic-variat…

OBJECTIVES:

Unwarranted geographic variation in spending has received intense scrutiny in the United States. However, few studies have compared variation in spending and surgical outcomes between the United States healthcare system and those of other nations. In this study, we compare the geographic variation in postsurgical outcomes and cost between the United States and Japan.

STUDY DESIGN:

This retrospective cohort study uses Medicare Part A data from the United States (2010-2011) and similar inpatient data from Japan (2012). Patients 65 years or older undergoing 1 of 5 surgeries (coronary artery bypass graft, abdominal aortic aneurysm repair, colectomy, pancreatectomy, or gastrectomy) were selected in the United States and Japan.

METHODS:

Reliability- and case-mix-adjusted coefficient of variation (COV) values were calculated using hierarchical modeling and empirical Bayes techniques for the following 5 outcomes: postoperative mortality, the development of a complication, death after complication (failure to rescue), length of stay, and the cost of the hospitalization. Sensitivity analyses were also performed by calculating patient demographic-and case-mix-adjusted COV values for each outcome using weighted age- and sex-standardized values.

RESULTS:

The variability of the postsurgical outcomes was uniformly lower in the United States compared with Japan. Cost variation was consistently higher in the United States for all surgeries.

CONCLUSIONS:

Although the US healthcare system may be more inefficient regarding costs, the presence of higher geographic variation in postoperative care in Japan, relative to the United States, suggests that the observed geographic variation in the United States-both for health expenditures and outcomes-is not a unique manifestation of its structural shortcomings.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
The American Journal of Managed Care
Authors
Paragraphs

Rationale: Although lung transplant recipient survival is better at higher volume centers, the effect of center volume on admission cost and early hospital readmission is unknown.

Objectives: To understand the association between transplant center volume and recipient risk-adjusted transplant admission cost, in-hospital mortality, and early hospital readmission in lung transplant recipients.

Methods: Medicare lung transplant recipients from May 4, 2005 to December 31, 2011 were identified through linkage of transplant registry and Medicare administrative claims. Transplant admission cost was extracted, adjusted for regional price variation, and compared across low-, intermediate-, and high-volume centers. A multivariable hierarchical generalized linear regression model was used to assess the effect of transplant center volume on recipient adjusted cost. Modified Poisson regression models were used to assess adjusted in-hospital mortality and early hospital readmission by transplant center volume.

Measurements and Main Results: There were 3,128 Medicare lung transplant recipients identified. Unadjusted transplant cost was lower at high-volume centers (mean, $131,352 [SD, ±$106,165]; median, $90,177; interquartile range [IQR], $79,165–$137,915) than at intermediate-volume (mean, $138,792 [SD, ±$106,270]; median, $93,024; IQR, $82,700–$154,857) or low-volume (mean, $143,609 [SD, ±$123,316]; median, $95,234; IQR, $83,052–$152,149) centers (P < 0.0001). After adjusting for recipient health risk, low-volume centers had an 11.66% greater transplant admission cost (P = 0.040), a 41% greater risk for in-hospital mortality (P = 0.015), and a 14% greater risk for early hospital readmission (P = 0.033) compared with high-volume centers. There was no significant difference in transplant cost, in-hospital mortality, or early hospital readmission between intermediate- and high-volume centers.

Conclusions: Lung transplant admission cost, in-hospital mortality, and early hospital readmission rate are lower at high-volume centers compared with low-volume centers.

 

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Annals of the American Thoracic Society
Authors
Paragraphs

Background. To characterize the association of antiretroviral drug combinations on risk of cardiovascular events.

Methods. Certain antiretroviral medications for human immunodeficiency virus (HIV) have been implicated in increasing risk of cardiovascular disease. However, antiretroviral drugs are typically prescribed in combination. We characterized the association of current exposure to antiretroviral drug combinations on risk of cardiovascular events including myocardial infarction, stroke, percutaneous coronary intervention, and coronary artery bypass surgery. We used the Veterans Health Administration Clinical Case Registry to analyze data from 24 510 patients infected with HIV from January 1996 through December 2009. We assessed the association of current exposure to 15 antiretroviral drugs and 23 prespecified combinations of agents on the risk of cardiovascular event by using marginal structural models and Cox models extended to accommodate time-dependent variables.

Results. Over 164 059 person-years of follow-up, 934 patients had a cardiovascular event. Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated with increased risk of cardiovascular event, with odds ratios ranging from 1.40 to 1.53. Five combinations were significantly associated with increased risk of cardiovascular event, all of which involved lamivudine. One of these—efavirenz, lamivudine, and zidovudine—was the second most commonly used combination and was associated with a risk of cardiovascular event that is 1.60 times that of patients not currently exposed to the combination (odds ratio = 1.60, 95% confidence interval, 1.25–2.04).

Conclusions. In the VA cohort, exposure to both individual drugs and drug combinations was associated with modestly increased risk of a cardiovascular event.

 

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Clinical Infectious Diseases
Authors
Eran Bendavid
Mark A. Hlatky
Mark Holodniy
Douglas K. Owens
Paragraphs

Importance:

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.

Objective:

To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.

Evidence Review:

The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.

Conclusions and Recommendations:

The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).

 

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Journal of the American Medical Association (JAMA)
Authors
Douglas K. Owens
Number
19
News Type
News
Date
Paragraphs

Japan's population is old and getting older. "Japan has one of the highest total dependency ratios that's ever been seen," said Karen Eggleston, a senior fellow at the Freeman Spogli Institute for International Studies (FSI), "about one elderly dependent for every worker in the population." The country's aging population raises questions about how to provide for the elderly both socially and economically. Along with Professor of Medicine Jay Bhattacharya and other members of the Center on the Demography and Economics of Health and Aging (CDEHA), Eggleston developed the Japanese Future Elderly Model to project the health and functional status of the country's elderly.

Hero Image
karen wide
All News button
1
Paragraphs

Importance  Elevations in levels of total, low-density lipoprotein, and non–high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovascular disease in adults.

Objective  To update the 2007 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in children, adolescents, and young adults.

Evidence Review  The USPSTF reviewed the evidence on screening for lipid disorders in children and adolescents 20 years or younger—1 review focused on screening for heterozygous familial hypercholesterolemia, and 1 review focused on screening for multifactorial dyslipidemia.

Findings  Evidence on the quantitative difference in diagnostic yield between universal and selective screening approaches, the effectiveness and harms of long-term treatment and the harms of screening, and the association between changes in intermediate outcomes and improvements in adult cardiovascular health outcomes are limited. Therefore, the USPSTF concludes that the balance of benefits and harms cannot be determined.

Conclusions and Recommendation  The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement)

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Journal of the American Medical Association (JAMA)
Authors
Douglas K. Owens
Number
6
Paragraphs

Background: The total population health benefits and costs of HIV preexposure prophylaxis (PrEP) for people who inject drugs (PWID) in the United States are unclear.

Objective: To evaluate the cost-effectiveness and optimal delivery conditions of PrEP for PWID.

Design: Empirically calibrated dynamic compartmental model.

Data Sources: Published literature and expert opinion.

Target Population: Adult U.S. PWID.

Time Horizon: 20 years and lifetime.

Intervention: PrEP alone, PrEP with frequent screening (PrEP+screen), and PrEP+screen with enhanced provision of antiretroviral therapy (ART) for individuals who become infected (PrEP+screen+ART). All scenarios are considered at 25% coverage.

Outcome Measures: Infections averted, deaths averted, change in HIV prevalence, discounted costs (in 2015 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

Results of Base-Case Analysis: PrEP+screen+ART dominates other strategies, averting 26 700 infections and reducing HIV prevalence among PWID by 14% compared with the status quo. Achieving these benefits costs $253 000 per QALY gained. At current drug prices, total expenditures for PrEP+screen+ART could be as high as $44 billion over 20 years.

Results of Sensitivity Analysis: Cost-effectiveness of the intervention is linear in the annual cost of PrEP and is dependent on PrEP drug adherence, individual transmission risks, and community HIV prevalence. Limitation: Data on risk stratification and achievable PrEP efficacy levels for U.S. PWID are limited.

Conclusion: PrEP with frequent screening and prompt treatment for those who become infected can reduce HIV burden among PWID and provide health benefits for the entire U.S. population, but, at current drug prices, it remains an expensive intervention both in absolute terms and in cost per QALY gained.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Annals of Internal Medicine
Authors
Margaret L. Brandeau
Keith Humphreys
Eran Bendavid
Mark Holodniy
Douglas K. Owens
Jeremy Goldhaber-Fiebert
Subscribe to Health Care